Advanced Search: Checkpoint Inhibitor Based

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201703028

Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

201904008

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

201911172

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma

201905195

A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

202004020

First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer

202004075

A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors

202005122

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

202005090

Phase 1/2 study of APR-246 in Combination with Pembrolizumab in Subjects with Solid Tumor Malignancies

202006073

An Open-label Phase 1b/2a Study of NT-I7 (Hyleukin-7) in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Advanced Solid Tumors

202001227

A Phase 1 Dose Escalation Trial of SYN125 Single Agent and in Combination with Fixed Dose SYN004 in Patients with Advanced Colorectal and Head and Neck Cancer